ClinicalTrials.gg
RecruitingNCT07632677Updated Nov 19, 2026

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

An observational study in Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis and Metabolic Dysfunction-associated Fatty Liver Disease, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 19, 2026Start date movedSponsor changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — 11 open to participants now, 12 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

Started
2026
with 2 others
Observational
7 of 19
6 open now
Primary completion
2027-12
later than 6 of 11 live
Registered
17th of 19
by date

Among the 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, this one is one of 3 that started in 2026, is one of 7 observational ones, reaches primary completion later than 6 of the 11 other live ones, and was the 17th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

11 of the 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, or all of them as a file.
02

Study summary

This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Read the detailed description

This study is a national, multicenter, real-world, cross-sectional observational trial designed to assess the clinical utility and diagnostic accuracy of the Liver Inflammation Index for identifying Metabolic Dysfunction-Associated Steatohepatitis (MASH) in patients with concurrent Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

The study plans to enroll a total of 10,000 participants across 22 major research centers in China. Data collection will be split into a prospective cohort (9,000 patients) and a retrospective cohort (1,000 patients). Each participating center will enroll between 100 and 2,000 subjects.

Study Procedures and Data Collection:

For all eligible participants, researchers will systematically collect comprehensive clinical data. This includes general demographic information, detailed past medical history, physical examination findings, and lifestyle questionnaires (assessing diet, physical activity, smoking, and alcohol consumption). Clinical assessments will involve standard laboratory tests to calculate the Liver Inflammation Index. Additionally, participants will undergo vibration-controlled transient elastography (using the iLivTouch device) to obtain the Ultrasound Attenuation Parameter (UAP) for steatosis grading and Liver Stiffness Measurement (LSM) for fibrosis staging.

Study Objectives:

The primary objective is to investigate the distribution and alterations of the Liver Inflammation Index in the Chinese T2DM and MAFLD population, and to evaluate the overall detection rate of MASH within this cohort.

Secondary objectives focus on stratifying the MASH detection rate based on several clinical variables:

The presence of comorbidities (including cardiovascular disease, chronic kidney disease, obesity, dyslipidemia, and hypertension).

The degree of hepatic steatosis (S1, S2, and S3), as determined by UAP results.

The severity of liver fibrosis (F0-F1, F2, F3, and F4), as determined by LSM results.

Demographic stratifications, including age, gender, and geographic region within China.

Identification of predictive risk factors associated with MASH in this specific patient population.

Exploratory Endpoints:

The study will explore the impact of modifiable, adverse lifestyle factors on the prevalence of MASH. Furthermore, a 5-year retrospective data collection (where hospital records permit) will be conducted to analyze the relationship between the MASH detection rate and various Liver-Related Events (LREs). LREs are defined as the occurrence of any of the following: Model for End-Stage Liver Disease (MELD) score ≥ 15, liver-related mortality, liver transplantation, progression to hepatocellular carcinoma, esophagogastric variceal bleeding, or hepatic decompensation (including ascites, overt hepatic encephalopathy, bacterial infections, and non-obstructive jaundice).

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • MASH - Metabolic Dysfunction-Associated Steatohepatitis
  • Metabolic Dysfunction-associated Fatty Liver Disease

Keywords

  • Type 2 Diabetes Mellitus
  • MASH
  • MAFLD
  • Liver inflammation index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients concurrently diagnosed with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Participants will be continuously enrolled from both outpatient clinics and inpatient departments across 22 major research centers and tertiary hospitals located in various geographic regions of China. This cohort represents a real-world clinical population seeking routine medical care, health evaluations, or regular follow-ups for their metabolic and endocrine conditions. Data will be collected through both prospective clinical assessments and retrospective medical record reviews.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged ≥18 years, with no restrictions on sex;
  2. Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Nonalcoholic) Fatty Liver Disease (2024 Edition), and additionally diagnosed with type 2 diabetes mellitus (T2DM) based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2024 Edition).

Exclusion criteria

Exclusion Criteria:

  1. Presence of unhealed wounds, scars, or other conditions in the right upper abdominal region that are unsuitable for ultrasonographic examination;
  2. Development of other liver diseases during follow-up, including viral hepatitis, drug-induced liver injury, liver disease, alcoholic liver disease, or other chronic liver diseases;
  3. History of hepatic decompensation;
  4. History of hepatectomy or liver transplantation;
  5. History of other ;
  6. Presence of vascular liver disease, cystic fibrosis-associated liver disease, sarcoidosis, polycystic liver disease, congenital or rare hereditary liver diseases, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure accompanied by hepatic venous congestion;
  7. History of transjugular intrahepatic portosystemic shunt (TIPS);
  8. Occurrence of acute hepatitis during follow-up (defined as levels >5 times the ) or acute-on-chronic liver failure (ACLF);
  9. Clinical or subclinical hypothyroidism or hyperthyroidism.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • T2DM with MAFLD

    Diagnostic Test: iLivTouch (Vibration-controlled transient elastography)

Interventions

  • Diagnostic testiLivTouch (Vibration-controlled transient elastography)

    A non-invasive diagnostic assessment performed using the iLivTouch device. This device simultaneously generates three key metrics: the Liver Inflammation Index (the primary target evaluated for its accuracy in detecting MASH), the Ultrasound Attenuation Parameter (UAP) for hepatic steatosis grading, and the Liver Stiffness Measurement (LSM) for fibrosis staging.

06

What researchers measure

Primary outcomes

  1. To evaluate the overall detection rate of MASH in the Chinese T2DM and MAFLD population.

    Time frame: Baseline

Secondary outcomes

  1. Proportion of Participants with MASH Stratified by Comorbidities

    To evaluate and compare the detection rate of Metabolic Dysfunction-Associated Steatohepatitis (MASH) among subgroups of patients with specific concurrent conditions, including cardiovascular disease, chronic kidney disease, obesity, dyslipidemia, and hypertension.

    Time frame: Baseline

  2. Proportion of Participants with MASH Stratified by Hepatic Steatosis Grades

    To analyze the differences in the detection rate of MASH across varying degrees of hepatic steatosis (mild \[S1\], moderate \[S2\], and severe \[S3\]), as determined by the Ultrasound Attenuation Parameter (UAP) via transient elastography.

    Time frame: Baseline

  3. Proportion of Participants with MASH Stratified by Liver Fibrosis Stages

    To assess the differences in the detection rate of MASH among patients with different stages of liver fibrosis (F0-F1, F2, F3, and F4), as classified by Liver Stiffness Measurement (LSM) via transient elastography.

    Time frame: Baseline

  4. Demographic Variations in MASH Detection Rate

    To determine the detection rate of MASH stratified by key demographic factors, specifically gender and predefined age groups, to identify potential population-specific distribution patterns.

    Time frame: Baseline

  5. Geographic Variations in MASH Detection Rate Across China

    To evaluate the regional differences in the detection rate of MASH among the enrolled cohort of T2DM and MAFLD patients across different geographical regions within China.

    Time frame: Baseline

  6. Identification of Risk Factors Associated with MASH

    To identify and evaluate independent demographic, clinical, and laboratory predictors (risk factors) associated with the presence of MASH using multivariable logistic regression modeling.

    Time frame: Baseline

Other outcomes

  1. Association Between Smoking and Alcohol Consumption Status and MASH Prevalence

    Smoking status and alcohol consumption status will be collected at baseline and recorded as binary variables (Yes/No). The association between smoking status, alcohol consumption status, and the prevalence of MASH will be evaluated.

    Time frame: Baseline

  2. Correlation Between MASH Detection and Retrospective Liver-Related Events (LREs)

    To analyze the relationship between the current presence of MASH and a history of Liver-Related Events (LREs) by collecting retrospective patient data (where hospital records permit). LREs are defined as the occurrence of any of the following: Model for End-Stage Liver Disease (MELD) score ≥ 15, liver-related mortality, liver transplantation, progression to hepatocellular carcinoma, esophagogastric variceal bleeding, or hepatic decompensation (such as ascites, overt hepatic encephalopathy, or bacterial infections).

    Time frame: Baseline

07

Study locations

21 of 21 sites recruiting
  • Department of Endocrinology, the First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui 233004, China
    Recruiting
    • Xiaolei Hu · Contact
  • Department of Endocrinology, The First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui, China
    Recruiting
    • Wei Wang · Contact
  • Department of Endocrinology, the Second Affiliated Hospital of Wannan Medical University
    Wuhu, Anhui 241000, China
    Recruiting
    • Junfei Gu · Contact
  • Department of Endocrinology, Zhujiang Hospital, Southern Medical University
    Guangzhou, Guangdong 510280, China
    Recruiting
    • Jia Sun · Contact
  • Department of Obesity and Metabolic Diseases, Panyu Hospital of Traditional Chinese Medicine
    Guangzhou, Guangdong 511495, China
    Recruiting
    • Hui Li · Contact
  • Department of Endocrinology, the Eighth Affiliated Hospital, Sun Yat-sen University
    Shenzhen, Guangdong 518033, China
    Recruiting
    • Yunfeng Shen · Contact
  • Department of Endocrinology, the First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
    Recruiting
    • Yingfen Qin · Contact
  • Department of Endocrinology, the Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
    Recruiting
    • Xin Liao · Contact
  • Department of Endocrinology, Hainan General Hospital
    Haikou, Hainan 570311, China
    Recruiting
    • Kaining Chen · Contact
  • Department of Endocrinology, Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
    Recruiting
    • Ling Gao · Contact
  • Department of Endocrinology, the First Affiliated Hospital of University of South China
    Hengyang, Hunan 421001, China
    Recruiting
    • Xinhua Xiao · Contact
  • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Yan Bi, MD, PhD · Contactbiyan@nju.edu.cn · 86-25-83-105302
    • Jin Li, MD, PhD · Contactjinli807@126.com · 86-25-83-105302
    • Yan Bi, MD, PhD · Principal investigator
    • Jin Li, MD, PhD · Sub investigator
  • Department of Endocrinology, the First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
    Recruiting
  • Department of Endocrinology, Xuzhou Central Hospital
    Xuzhou, Jiangsu 221009, China
    Recruiting
    • Houfa Geng · Contact
  • Department of Endocrinology, the Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
    Recruiting
    • Yangang Wang · Contact
  • Department of Metabolic Diseases and Weight Management, Weifang People's Hospital
    Weifang, Shandong 261000, China
    Recruiting
    • Haixia Liu · Contact
  • Department of Endocrinology, ZhongShan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
  • Department of Endocrinology and Metabolism, Xijing Hospital, Air Force Medical University
    Xi’an, Shanxi 710032, China
    Recruiting
    • Xiangyang Liu · Contact
  • Department of Endocrinology, the Third People's Hospital of Yunnan Province
    Kunming, Yunnan 650011, China
    Recruiting
    • Li Gui · Contact
  • Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310020, China
    Recruiting
    • Jiaqiang Zhou · Contact
  • Department of Endocrinology, The First Affiliated Hospital of Medical School of Zhejiang University
    Hangzhou, Zhejiang 325000, China
    Recruiting
    • Xiaomu Li · Contact
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant data may be timely shared with qualified researchers upon request, subject to review and approval.

Supporting information: Study protocol, Informed consent form

Time frame: Data will become available after study completion and primary publication for 3 years.

Access criteria: Data requests require a valid research proposal and signed data use agreement. Approval is contingent on compliance with applicable laws and ethical guidelines.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2026
First posted
Jun 8, 2026
StartActual
May 7, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 3 sites removed
Show 2 added (2 China)
  • Department of Endocrinology, The First Affiliated Hospital of University of Science and Technology of China · Hefei, China
  • Department of Endocrinology, The First Affiliated Hospital of Medical School of Zhejiang University · Hangzhou, China
Show 3 removed
  • Department of Endocrinology, the Second Affiliated Hospital of Anhui Medical University · Hefei, China
  • Department of Endocrinology, the First Affiliated Hospital of Henan University of CM · Zhengzhou, China
  • Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
Nov 19, 2026
Start date
May 15, 2026→May 7, 2026 (actual)
Nov 19, 2026
Sponsor
Collaborators added: The First Affiliated Hospital of Air Force Medical University·The First Affiliated Hospital of University of Science and Technology of China·First Affiliated Hospital of Zhejiang University; collaborators removed: First Affiliated Hospital of Wenzhou Medical University·The Second Hospital of Anhui Medical University·The First Affiliated Hospital of Air Force Medicial University·The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    2 sites added, 3 sites removed
    Show 2 added (2 China)
    • Department of Endocrinology, The First Affiliated Hospital of University of Science and Technology of China · Hefei, China
    • Department of Endocrinology, The First Affiliated Hospital of Medical School of Zhejiang University · Hangzhou, China
    Show 3 removed
    • Department of Endocrinology, the Second Affiliated Hospital of Anhui Medical University · Hefei, China
    • Department of Endocrinology, the First Affiliated Hospital of Henan University of CM · Zhengzhou, China
    • Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    Start date May 15, 2026→May 7, 2026 (now actual)
    Sponsor Collaborators added: The First Affiliated Hospital of Air Force Medical University·The First Affiliated Hospital of University of Science and Technology of China·First Affiliated Hospital of Zhejiang University; collaborators removed: First Affiliated Hospital of Wenzhou Medical University·The Second Hospital of Anhui Medical University·The First Affiliated Hospital of Air Force Medicial University·The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07632677
Collaborators
Fudan University, The First Affiliated Hospital of Soochow University, Xuzhou Central Hospital, The First Affiliated Hospital of Bengbu Medical University, The Affiliated Hospital of Qingdao University, Weifang People's Hospital, Panyu Hospital of Traditional Chinese Medicine, Southern Medical University, China, First Affiliated Hospital of Guangxi Medical University, Zunyi Medical College, The First Affiliated Hospital of Air Force Medical University, Hainan General Hospital, The Third People's Hospital of Yunnan Province, Sir Run Run Shaw Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Wannan Medical College, Renmin Hospital of Wuhan University, The First Affiliated Hospital of University of South China, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Zhejiang University
Responsible party
Yan Bi (Chief Physician, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Jun 8, 2026
Start date
May 7, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Yan Bi, MD,PhD
Contact
biyan@nju.edu
86-25-83-105302
Jin Li, MD,PhD
Contact
jinli807@126.com
86-25-83-105302
Yan Bi, MD,PhD
principal investigator · Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion